Cellect Biotechnology Ltd APOP is trading higher Monday after the company announced shareholder approval of the strategic merger with Quoin Pharmaceuticals.
Approximately 99% of the votes were in favor of approving the proposal. The strategic merger is expected to close in October.
Cellect Biotechnology is a biotechnology company that has developed a novel technology platform known as ApoGraft that functionally selects cells in order to improve the safety and efficacy of regenerative medicine and cell therapies.
Quoin Pharmaceuticals is a specialty pharmaceutical company focused on rare and orphan diseases.
APOP Price Action: Cellect Biotechnology is making new 52-week highs in trading today.
The stock was up 12.60% at $21.34 at time of publication.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.